Thyroid cancer: metabolic gene signature predicts dedifferentiation

  • Ma B & al.
  • J Clin Endocrinol Metab
  • 3 Apr 2019

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • A metabolic gene signature identified by transcriptional analysis is associated with dedifferentiation of papillary thyroid cancer (PTC).

Why this matters

  • This metabolic gene signature may be a useful biomarker of dedifferentiation, which is associated with poor clinical outcomes.

Key results

  • Expression of the metabolic genes LPCAT2 (OR, 0.424; P=.036), ACOT7 (OR, 11.175; P<.001>, HSD17B8 (OR, 0.049; P<.001>, PDE8B (OR, 0.357; P<.001 and>ST3GAL1 (OR, 0.190; P<.001 were associated with the low-differentiated phenotype in multivariate analysis.>
  • The gene signature had an area under the curve of 0.90 for predicting a low-differentiated phenotype.
  • The gene signature risk score was associated with T3/T4 stage (OR, 1.651; P=.026), lymph node metastasis (OR, 2.495; P<.001 and>BRAF-V600E mutation (OR, 3.213; P<.001 inversely associated with the>RAS mutation (OR, 0.124; P=.001) in multivariate analysis.

Study design

  • 502 patients with PTC from The Cancer Genome Atlas cohort.
  • Funding: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

Limitations

  • Retrospective study.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit